{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:01:35Z","timestamp":1792612895232,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["40-05116"],"award-info":[{"award-number":["40-05116"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["03ZU1111CA"],"award-info":[{"award-number":["03ZU1111CA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003185","name":"Fraunhofer Society for the Advancement of Applied Research","doi-asserted-by":"publisher","award":["131-600004"],"award-info":[{"award-number":["131-600004"]}],"id":[{"id":"10.13039\/501100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102140","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:20:20Z","timestamp":1772731220000},"page":"102140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies"],"prefix":"10.1016","volume":"28","author":[{"given":"Katharina Eva","family":"Ruppel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-059X","authenticated-orcid":false,"given":"Philipp","family":"L\u00fcckemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1072-3061","authenticated-orcid":false,"given":"Alexander","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Stahringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-9160","authenticated-orcid":false,"given":"Ulrike","family":"K\u00f6hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3384-5651","authenticated-orcid":false,"given":"Dominik","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102140_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102140_bib0002","series-title":"From Biology to Novel Therapies","article-title":"T-Cell and NK-Cell Lymphomas","author":"Querfeld","year":"2019"},{"key":"10.1016\/j.jcyt.2026.102140_bib0003","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2004-01-0002","article-title":"A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories","volume":"104","author":"Herling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0005","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41375-025-02574-x","article-title":"Emerging T-cell lymphomas after CAR T-cell therapy","volume":"39","author":"Braun","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102140_bib0006","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1230629","article-title":"Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0008","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3324\/haematol.2021.280275","article-title":"Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas","volume":"108","author":"Ngu","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102140_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092532","article-title":"Education and empowering special forces to eradicate secret defectors: immune system-based treatment approaches for mature T- and NK-Cell malignancies","volume":"15","author":"Braun","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2026.102140_bib0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bmt.2014.243","article-title":"Graft-versus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation","volume":"50","author":"Mamez","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jcyt.2026.102140_bib0011","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/TCRM.S134398","article-title":"Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis","volume":"13","author":"Guarnera","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jcyt.2026.102140_bib0012","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1016\/S2352-3026(24)00171-6","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study","volume":"11","author":"Herrera","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","article-title":"CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?","volume":"9","author":"Maciocia","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102140_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-025-06474-z","article-title":"Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma","author":"Maraglino","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0016","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102140_bib0017","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102140_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11010165","article-title":"CAR T-cell immunotherapy treating T-ALL: challenges and opportunities","volume":"11","author":"Ren","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jcyt.2026.102140_bib0019","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem cell Res Ther"},{"key":"10.1016\/j.jcyt.2026.102140_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \"Off-The-Shelf\" allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0021","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2026.102140_bib0023","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102140_bib67","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102140_bib0024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0025","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J clin oncol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0026","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/jac\/dkq261","article-title":"Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection","volume":"65","author":"Bruno","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcyt.2026.102140_bib0027","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102140_bib0022","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2026.102140_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102140_bib0029","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-024-03179-5","article-title":"In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma","volume":"43","author":"Krug","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102140_bib0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12015-019-09876-5","article-title":"Targeting T cell malignancies using CD4CAR T-Cells and implementing a natural safety switch","volume":"15","author":"Ma","year":"2019","journal-title":"Stem cell rev rep"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2026.102140_bib0031","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2019-122789","article-title":"First-in-human CD4 CAR clinical trial on peripheral T-cell lymphoma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0032","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.4c03135","article-title":"Efficient capture and traceless release of functional CD8+ T Cells with a microfluidic chip for enhanced in vitro and in vivo CD4-CAR transduction","author":"Abdulla","year":"2024","journal-title":"Anal Chem"},{"key":"10.1016\/j.jcyt.2026.102140_bib0033","doi-asserted-by":"crossref","first-page":"bpaf015","DOI":"10.1093\/biomethods\/bpaf015","article-title":"Protocol for isolation and expansion of natural killer cells from human peripheral blood scalable for clinical applications","volume":"10","author":"Kundu","year":"2025","journal-title":"Biol Methods protoc"},{"key":"10.1016\/j.jcyt.2026.102140_bib0034","series-title":"Cancer-Targeted Drug Delivery","first-page":"63","article-title":"Advances in the manufacturing of CAR-NK Cells for cancer immunotherapy","author":"Uhlig","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102140_bib0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/hgtb.2019.039","article-title":"Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human nk cells and alpharetroviral chimeric antigen receptor engineering","volume":"30","author":"Oberschmidt","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jcyt.2026.102140_bib0036","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/nar\/23.4.628","article-title":"A transient three-plasmid expression system for the production of high titer retroviral vectors","volume":"23","author":"Soneoka","year":"1995","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcyt.2026.102140_bib0037","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","article-title":"Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs","volume":"124","author":"Girard-Gagnepain","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0038","article-title":"Optimized conditions for gene transduction into primary immune cells using viral vectors","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102140_bib0039","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41590-022-01394-w","article-title":"NgR1 is an NK cell inhibitory receptor that destabilizes the immunological synapse","volume":"24","author":"Oh","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0064","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/0008-5472.CAN-25-0881","article-title":"Multiomics profiling of T-cell leukemia and lymphoma enables targeted therapeutic discovery","volume":"86","author":"Ianevski","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102140_bib0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13104-016-1900-2","article-title":"AdapterRemoval v2: rapid adapter trimming, identification, and read merging","volume":"9","author":"Schubert","year":"2016","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jcyt.2026.102140_bib0041","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0042","doi-asserted-by":"crossref","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"GigaScience"},{"key":"10.1016\/j.jcyt.2026.102140_bib0043","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btac166","article-title":"Analysing high-throughput sequencing data in Python with HTSeq 2.0","author":"Putri","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2026.102140_bib0044","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01035","article-title":"The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance","volume":"10","author":"Stahl","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0046","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1074\/mcp.M600310-MCP200","article-title":"Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface","volume":"6","author":"Weinzierl","year":"2007","journal-title":"Mol Cell Proteom"},{"key":"10.1016\/j.jcyt.2026.102140_bib0047","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0048","article-title":"CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma","volume":"14","author":"Ciulean","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102140_bib0049","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102140_bib0050","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2026.102140_bib0051","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2546443","article-title":"Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies","volume":"14","author":"Schindler-Wnek","year":"2025","journal-title":"Oncoimmunology"},{"issue":"Suppl_1","key":"10.1016\/j.jcyt.2026.102140_bib0052","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V130.Suppl_1.889.889","article-title":"Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) As maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir Trial","volume":"130","author":"Vey","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0053","article-title":"Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0054","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1593\/neo.04316","article-title":"Downregulation and\/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma","volume":"6","author":"Raffaghello","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.jcyt.2026.102140_bib0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin oncol"},{"key":"10.1016\/j.jcyt.2026.102140_bib0056","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199902183400703","article-title":"Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency","volume":"340","author":"Buckley","year":"1999","journal-title":"N Engl j med"},{"key":"10.1016\/j.jcyt.2026.102140_bib0057","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102140_bib0058","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/bmt.2010.68","article-title":"Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective","volume":"46","author":"Schub","year":"2011","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jcyt.2026.102140_bib0059","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137990","article-title":"Single-cell transcriptomics of alloreactive CD4+ T cells over time reveals divergent fates during gut graft-versus-host disease","volume":"5","author":"Engel","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2026.102140_bib0060","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102140_bib65","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2026.102140_bib0061","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115178","article-title":"Advances in clinical NK cell studies: donor selection, manufacturing and quality control","volume":"5","author":"Koehl","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2026.102140_bib0062","doi-asserted-by":"crossref","first-page":"250.e1","DOI":"10.1016\/j.jtct.2022.02.008","article-title":"A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors","volume":"28","author":"Otegbeye","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102140_bib0063","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jcyt.2020.03.240","article-title":"Seeding density is critical for optimizing scalable feeder-free natural killer cell expansion","volume":"22","author":"Johnson","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102140_bib66","doi-asserted-by":"crossref","first-page":"1804945","DOI":"10.3389\/fbioe.2026.1804945","article-title":"Homogeneous shear distribution improves NK-92 cell cytotoxicity in a clinically relevant 2 L membrane-stirred bioreactor","volume":"14","author":"von Werz","year":"2026","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926001015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926001015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:20:22Z","timestamp":1781018422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926001015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926001015"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102140","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of a novel CD4 specific CAR NK cell therapy for T-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102140"}}